Supplement

Cost Savings in Migraine Associated with Less Chest Pain on New Triptan Therapy

Published Online: February 01, 2002
Joseph T. Wang, MS; Charles E. Barr, MD; Yas Torigoe, PhD; Elaine Wang, BS; Clayton R. Rowland, PhD; Scott D. Goldfarb, PharmD, MBA
Log in to access PDF
Issue: New Approaches to the Treatment of Migraine: Clinical and Economic Impact
SUPPLEMENT CONTENT
Participating Faculty
Introduction
Lisa K. Mannix, MD
Migraine: Diagnosis, Management, and New Treatment Options
R. Michael Gallagher, DO; F. Michael Cutrer, MD
Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability
Randal L. Von Seggern, PharmD, BCPS
Economic Comparison of Oral Triptans for Management of Acute Migraine: Implications for Managed Care
C.E. Reeder, RPh, PhD; Sharm Steadman, PharmD, BCPS, FASHP; Scott D. Goldfarb, PharmD, MBA
Health Outcomes Evaluations: Estimating the Impact of Almotriptan in Managed Care Settings
Kevin W. Mayo, PhD; Jane T. Osterhaus, PhD
Almotriptan Versus Sumatriptan in Migraine Treatment: Direct Medical Costs of Managing Adverse Chest Symptoms
Lisa K. Mannix, MD; James U. Adelman, MD, FACP; Scott D. Goldfarb, PharmD, MBA; Randal L. Von Seggern, PharmD, BCPS; Chris M. Kozma, PhD
Cost Savings in Migraine Associated with Less Chest Pain on New Triptan Therapy
Joseph T. Wang, MS; Charles E. Barr, MD; Yas Torigoe, PhD; Elaine Wang, BS; Clayton R. Rowland, PhD; Scott D. Goldfarb, PharmD, MBA
Click for Full Issue
More on AJMC.COM
No Result Found
About Us | Contact Us | Advertise | Terms & Conditions | Press Room | Copyright HCPLive 2006-2013 | Intellisphere, LLC. All Rights Reserved.
Partner Websites: Pharmacy Times | Targeted Therapies | PainLive | HCPLive | ONCLive